Condition

Lipoatrophy

ClinicalTrials.gov condition label

Clinical trials6

Recruiting0

Common interventions10

Lead sponsors shown6

Clinical trials

6 shown

Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.NCT04860063 · 2021-04-01

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)NCT02914886 · 2016-09-01

Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected PatientsNCT00978237 · 2009-10-01

Effects of a Uridine Supplement on HIV Infected Adults With LipoatrophyNCT00307164 · 2006-09-01

Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.NCT00139178 · 2004-03-01

Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral TherapyNCT00312832 · 2004-01-01

Common interventions

ApidraDRUG1 BerberineDRUG1 current insulinDRUG1 Different HAART regimensDRUG1 EFVDRUG1 LPV/rDRUG1 NucleomaxXDRUG1 NucleomaxX placeboDRUG1 PlaceboDRUG1 switching; dose reductionDRUG1

Leading sponsors

Danish HIV Research Group1 Hospital Civil de Guadalajara1 Hospital Clinic of Barcelona1 Juan A. Arnaiz1 Kinderkrankenhaus auf der Bult1 National Institute of Allergy and Infectious Diseases (NIAID)1

Trial status mix

COMPLETED5

UNKNOWN1

Phase mix

PHASE43

PHASE32

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.